EICHOR
● Completed
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
Condition: Small Cell Lung Cancer · Sponsor: G1 Therapeutics, Inc.
About this study
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing antitumor efficacy when administered with carboplatin, etoposide, and atezolizumab (E/P/A) therapy in first line treatment for patients with newly diagnosed extensive-stage SCLC. The study was a randomized, double-blinded, placebo-controlled design. Approximately, 100 patients were randomized to trilaciclib + E/P/A or placebo + E/P/A in the study.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (45)
| Beverly Hills Cancer Center | Beverly Hills, California, United States | — |
| St. Jude Heritage Healthcare | Fullerton, California, United States | — |
| Loma Linda University | Loma Linda, California, United States | — |
| UCLA Medical Center - Santa Monica Hematology And Oncology | Santa Monica, California, United States | — |
| Redwood Regional Medical Group (RRMG) - Fountain Grove | Santa Rosa, California, United States | — |
| Singing River Health System | Whittier, California, United States | — |
| Piedmont Cancer Institute | Atlanta, Georgia, United States | — |
| Northside Hospital - Georgia Cancer Specialists | Atlanta, Georgia, United States | — |
| Joliet Oncology-Hematology Associates | Joliet, Illinois, United States | — |
| Horizon Oncology Center | Lafayette, Indiana, United States | — |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | — |
| St. Louis Cancer Care, LLP, North County | Bridgeton, Missouri, United States | — |
+ 33 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03041311